SELLAS Life Sciences Group, Inc. — Director's Dealing 2011

Oct 28, 2011

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2011-10-17

Reporting Person: Lee Kwang (Principal Accounting Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$0.76	2021-10-16	Common Stock (60000)		Direct

Footnotes

F1: Option vests in 12 equal quarterly installments following the date of grant.